These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 10986736)

  • 1. Implications for the serogroup incidence of meningococcal disease after the introduction of the MenC vaccine.
    Clarke SC; Edwards GF
    Scott Med J; 2000 Jun; 45(3):67. PubMed ID: 10986736
    [No Abstract]   [Full Text] [Related]  

  • 2. Epidemiology and meningococcal serogroup distribution in the United States.
    Hershey JH; Hitchcock W
    Clin Pediatr (Phila); 2010 Jun; 49(6):519-24. PubMed ID: 20507868
    [No Abstract]   [Full Text] [Related]  

  • 3. Meningococcal disease due to serogroup Y in Scotland, 1992-1999.
    Clarke SC; Reid J; Thom L; Denham BC; Edwards GF
    Br J Biomed Sci; 2001; 58(1):17-9. PubMed ID: 11284218
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Continuing increase in the incidence of serogroup C meningococcal disease. Should we decide to vaccinate?].
    Soult Rubio JA; Muñoz Sáez M; López Castilla JD; Rodríguez Becerra A; Romero Parreño A; Tovaruela Santos A
    An Esp Pediatr; 2000 Jul; 53(1):75-6. PubMed ID: 11203416
    [No Abstract]   [Full Text] [Related]  

  • 5. A decade of herd protection after introduction of meningococcal serogroup C conjugate vaccination.
    Bijlsma MW; Brouwer MC; Spanjaard L; van de Beek D; van der Ende A
    Clin Infect Dis; 2014 Nov; 59(9):1216-21. PubMed ID: 25069869
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neisseria meningitidis serogroup W135 isolates associated with the ET-37 complex.
    Popovic T; Sacchi CT; Reeves MW; Whitney AM; Mayer LW; Noble CA; Ajello GW; Mostashari F; Bendana N; Lingappa J; Hajjeh R; Rosenstein NE
    Emerg Infect Dis; 2000; 6(4):428-9. PubMed ID: 10905984
    [No Abstract]   [Full Text] [Related]  

  • 7. Meningococcal disease epidemiology in Brazil (2005-2018) and impact of MenC vaccination.
    Aparecido Nunes A; De Jesus Lopes De Abreu A; Cintra O; A C T Cintra M; Barbosa Coelho E; Nogueira Castro De Barros E
    Vaccine; 2021 Jan; 39(3):605-616. PubMed ID: 33358262
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in the evolution of meningococcal disease, 2001-2008, Catalonia (Spain).
    Martínez AI; Dominguez A; Oviedo M; Minguell S; Jansa JM; Codina G; Vazquez JA;
    Vaccine; 2009 May; 27(25-26):3496-8. PubMed ID: 19200816
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evolving meningococcal immunization strategies.
    Sáfadi MA; Bettinger JA; Maturana GM; Enwere G; Borrow R;
    Expert Rev Vaccines; 2015 Apr; 14(4):505-17. PubMed ID: 25494168
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serogroup B meningococcal disease: new outbreaks, new strategies.
    Wenger JD
    JAMA; 1999 Apr; 281(16):1541-3. PubMed ID: 10227326
    [No Abstract]   [Full Text] [Related]  

  • 11. Guidelines for control of meningococcal disease. Laboratory Centre for Disease Control.
    Can Fam Physician; 1994 Dec; 40():2121-3. PubMed ID: 7888825
    [No Abstract]   [Full Text] [Related]  

  • 12. Evaluation of serogroup C and ACWY meningococcal vaccine programs: projected impact on disease burden according to a stochastic two-strain dynamic model.
    Vickers DM; Anonychuk AM; De Wals P; Demarteau N; Bauch CT
    Vaccine; 2015 Jan; 33(1):268-75. PubMed ID: 24103896
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Meningococcal disease falls in vaccine recipients.
    Commun Dis Rep CDR Wkly; 2000 Apr; 10(15):133, 136. PubMed ID: 10793463
    [No Abstract]   [Full Text] [Related]  

  • 14. [Evolution of meningococcal disease in the community of Madrid. Effectiveness of antimeningococcal A+C vaccination].
    Gutiérrez Rodríguez MA; Ramírez Fernández R; García Gutiérrez J; Moreno Civantos A; Hernando García M; Arce Arnáez A; Sendra Gutiérrez JM; Bueno Vallejos R
    Rev Esp Salud Publica; 2000; 74(4):397-403. PubMed ID: 11031849
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in the Population Structure of Invasive Neisseria meningitidis in the United States After Quadrivalent Meningococcal Conjugate Vaccine Licensure.
    Wang X; Shutt KA; Vuong JT; Cohn A; MacNeil J; Schmink S; Plikaytis B; Messonnier NE; Harrison LH; Clark TA; Mayer LW
    J Infect Dis; 2015 Jun; 211(12):1887-94. PubMed ID: 25556253
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Surveillance of invasive meningococcal disease in the Czech Republic.
    Kriz P
    Euro Surveill; 2004 Nov; 9(11):37-9. PubMed ID: 15591689
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neisseria meningitidis carriage during an outbreak of serogroup C disease.
    Patrick DM; Champagne S; Goh SH; Arsenault G; Thomas E; Shaw C; Rahim T; Taha F; Bigham M; Dubenko V; Skowronski D; Brunham RC
    Clin Infect Dis; 2003 Nov; 37(9):1183-8. PubMed ID: 14557962
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Meningococcal Group W Disease in Infants and Potential Prevention by Vaccination.
    Parikh SR; Campbell H; Beebeejaun K; Ribeiro S; Gray SJ; Borrow R; Ramsay ME; Ladhani SN
    Emerg Infect Dis; 2016 Aug; 22(8):1505-7. PubMed ID: 27433852
    [No Abstract]   [Full Text] [Related]  

  • 19. The impact of meningococcal serogroup C conjugate vaccine in Scotland.
    Mooney JD; Christie P; Robertson C; Clarke SC
    Clin Infect Dis; 2004 Aug; 39(3):349-56. PubMed ID: 15307001
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Meningococcal vaccine development--from glycoconjugates against MenACWY to proteins against MenB--potential for broad protection against meningococcal disease.
    Dull PM; McIntosh ED
    Vaccine; 2012 May; 30 Suppl 2():B18-25. PubMed ID: 22607895
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.